Pieter S Siebenga Selected Research

Pain (Aches)

1/2022	A phase I, randomized, double-blind, placebo-controlled, single- and multiple dose escalation study evaluating the safety, pharmacokinetics and pharmacodynamics of VX-128, a highly selective Nav 1.8 inhibitor, in healthy adults.
1/2021	A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Pharmacodynamic Effects of VX-150, a Highly Selective NaV1.8 Inhibitor, in Healthy Male Adults.
8/2019	Analgesic potential of PF-06372865, an α2/α3/α5 subtype-selective GABAA partial agonist, in humans.
1/2019	Reproducibility of a battery of human evoked pain models to detect pharmacological effects of analgesic drugs.
1/2019	The ultraviolet B inflammation model: Postinflammatory hyperpigmentation and validation of a reduced UVB exposure paradigm for inducing hyperalgesia in healthy subjects.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Pieter S Siebenga Research Topics

Disease

5	Pain (Aches) 01/2022 - 01/2019
1	Neuralgia (Stump Neuralgia) 08/2019
1	Long Term Adverse Effects 01/2019

Drug/Important Bio-Agent (IBA)

4	Analgesics (Analgesic Drugs)IBA 01/2021 - 01/2019
2	Pregabalin (Lyrica)FDA Link 08/2019 - 01/2019
1	Voltage-Gated Sodium ChannelsIBA 01/2022
1	Capsaicin (Zostrix)FDA Link 01/2021
1	PF-06372865IBA 08/2019
1	Ibuprofen (Motrin)FDA LinkGeneric 01/2019
1	1-phenyl-3,3-dimethyltriazene (PDT)IBA 01/2019

Therapy/Procedure

1	Analgesia 01/2021